Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative ...

Cassava Sciences, a Texas biopharma company, had developed simufilam to treat (and possibly cure) Alzheimer’s disease, the most common form of dementia that afflicts tens of millions of people ...

A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The plaintiffs ...

Cassava Sciences' Phase 3 RETHINK-ALZ trial for simufilam in Alzheimer's failed decisively, with the company discontinuing its second Phase 3 trial and reducing its workforce by 33%. The company ...

Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did meet its co-primary endpoints in a phase 3 trial. Those endpoints were ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Take two at bedtime. That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re ...

Please note that in November 2024, Cassava faced a massive setback after it reported that its lead and only pipeline drug, simufilam, failed to meet the primary endpoints in a late study for AD.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment ...